US 11040984
Quinazoline compound for EGFR inhibition
granted A61KA61K45/06A61P
Quick answer
US patent 11040984 (Quinazoline compound for EGFR inhibition) held by Medshine Discovery Inc. expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Medshine Discovery Inc.
- Grant date
- Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K45/06, A61P, A61P35/00